Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others?
暂无分享,去创建一个
[1] A. Tsafriri,et al. Molecular aspects of mammalian ovulation. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[2] M. Brännström,et al. Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls. , 2001, European journal of obstetrics, gynecology, and reproductive biology.
[3] R. Jaffe,et al. Role of vascular endothelial growth factor in ovarian physiology and pathology. , 2000, Fertility and sterility.
[4] I. Asplin,et al. The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. , 2000, The Journal of biological chemistry.
[5] Y. S. Yang,et al. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. , 2000, Human reproduction.
[6] W. Jelkmann,et al. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. , 1999, Human reproduction.
[7] R. Stones,et al. Southampton, Southampton, UK , 2022 .
[8] J. Williamson,et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. , 1999, Investigative ophthalmology & visual science.
[9] U. Waldenström,et al. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study. , 1999, Human reproduction.
[10] V. Barak,et al. Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome? , 1999, The Journal of reproductive medicine.
[11] A. Yuzpe,et al. Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. , 1999, Fertility and sterility.
[12] S. Campbell,et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. , 1999, Fertility and sterility.
[13] E. Levin,et al. Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. , 1998, The Journal of clinical investigation.
[14] M. Dhont,et al. Prevention of severe ovarian hyperstimulation by coasting. , 1998, Fertility and sterility.
[15] K. Kasai,et al. Power and colour Doppler ultrasonography for the evaluation of the vasculature of the human corpus luteum. , 1998, Human reproduction.
[16] A. Genazzani,et al. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. , 1998, Fertility and sterility.
[17] S. Smith. Angiogenesis, vascular endothelial growth factor and the endometrium. , 1998, Human reproduction update.
[18] S. Campbell,et al. Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. , 1998, Human reproduction.
[19] R. Stouffer,et al. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. , 1997, Fertility and sterility.
[20] A. Ferrari,et al. Expression of vascular endothelial growth factor in human luteinizing granulosa cells and its correlation with the response to controlled ovarian hyperstimulation. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[21] P. Wood,et al. Variation in Detection of VEGF in Maternal Serum by Immunoassay and the Possible Influence of Binding Proteins , 1997, Annals of clinical biochemistry.
[22] H. Jacobs,et al. Severe ovarian hyperstimulation syndrome: serum and ascitic fluid concentrations of vascular endothelial growth factor. , 1997, Current opinion in obstetrics & gynecology.
[23] J. Schenker,et al. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.
[24] N. Ferrara,et al. The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.
[25] Z. Ben-Rafael,et al. The immune system in severe ovarian hyperstimulation syndrome. , 1996, Israel journal of medical sciences.
[26] D. Redmer,et al. Angiogenesis in the ovary. , 1996, Reviews of reproduction.
[27] S. Berga,et al. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. , 1996, Fertility and sterility.
[28] M. Breckwoldt,et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. , 1995, The Journal of clinical endocrinology and metabolism.
[29] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[30] A. Pedram,et al. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome , 1995 .
[31] D. Connolly,et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome , 1994, The Lancet.
[32] S. Soker,et al. Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. , 1993, The Journal of biological chemistry.
[33] D. Brann,et al. Characterization of the kinin system in the ovary during ovulation in the rat. , 1992, Biology of reproduction.
[34] E. Wallach,et al. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. , 1992, Fertility and sterility.
[35] J. Winer,et al. The vascular endothelial growth factor family of polypeptides , 1991, Journal of cellular biochemistry.
[36] T. Curry,et al. Alpha 2-macroglobulin and tissue inhibitor of metalloproteinases: collagenase inhibitors in human preovulatory ovaries. , 1990, Endocrinology.
[37] J. Richards,et al. Hormonal regulation and tissue-specific localization of alpha 2-macroglobulin in rat ovarian follicles and corpora lutea. , 1989, Endocrinology.
[38] A. Golan,et al. Ovarian hyperstimulation syndrome: an update review. , 1989 .
[39] S. Shapiro,et al. Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. , 1983, Fertility and sterility.
[40] J. Schenker,et al. Ovarian Hyperstimulation Syndrome: A Current Survey , 1978 .
[41] H. Kentenich,et al. Cytokines in the follicular fluid of stimulated and non-stimulated human ovaries; is ovulation a suppressed inflammatory reaction? , 1999, Human reproduction.
[42] W. Jelkmann,et al. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. , 1998, Human reproduction.
[43] K. James. Interactions between cytokines and α2-macroglobulin , 1990 .
[44] K. James. Interactions between cytokines and alpha 2-macroglobulin. , 1990, Immunology today.